

# Mrkt BUZZ, Immunovia: Regulatory tailwind in the USA following ruling against the FDA

Carlsquare Equity Research has published a comment following a court ruling against the FDA regarding laboratory-developed tests.

Read the full comment here.

## **About Carlsquare**

Carlsquare is a global research firm and financial advisor, focusing on M&A, Equity Research and Growth Equity. Carlsquare has 150 employees with deep sector knowledge in all 11 GICS sectors. The senior equity research team has extensive experience about the stock environment and several business sectors. The team produces company research reports, independent valuations and trading notes. The group have offices in Canada, Denmark, France, Germany, Poland, Sweden, United Kingdom and United States. Read more

### **Contacts**

# **MARKUS AUGUSTSSON**

Head of Equity Research

markus.augustsson@carlsquare.com
+46 (0)76 235 03 20

# **NIKLAS ELMHAMMER**

Senior Equity Analyst niklas.elmhammer@carlsquare.com +46 (0)70 898 39 59

### **Attachments**

Mrkt BUZZ, Immunovia: Regulatory tailwind in the USA following ruling against the FDA